Bayer's $2.45B Perfuse Therapeutics Acquisition: A New Chapter in Ophthalmology Drug-Device Convergence

The Deal at a Glance

On May 6, 2026, Bayer AG and Perfuse Therapeutics Inc. jointly announced a definitive agreement under which Bayer will fully acquire the San Francisco-based clinical-stage biopharmaceutical company in a transaction valued at up to $2.45 billion. The deal marks Bayer's first pharmaceutical acquisition since 2021 and its potential largest since the $4 billion Asklepios BioPharmaceutical (AskBio) buyout in 2020.

The transaction centers on a single asset: PER-001, a first-in-class small molecule endothelin receptor antagonist delivered via a bio-erodible intravitreal implant. The drug-device combination product is currently in Phase II clinical development for open-angle glaucoma and diabetic retinopathy -- two of the world's leading causes of irreversible blindness.

Who Are the Players

Bayer AG: A Pharma Giant Rebuilding Its Pipeline

Bayer is one of the world's largest life sciences companies, with a pharmaceuticals division that generated approximately EUR 18 billion in revenue in 2025. The Leverkusen-based conglomerate has a long-standing presence in ophthalmology, most notably through its exclusive ex-US marketing rights to Eylea (aflibercept) 2 mg and Eylea 8 mg (marketed as Eylea HD in the United States), which Regeneron Pharmaceuticals developed and commercializes domestically.

The Perfuse acquisition comes at a pivotal moment for Bayer. Since the appointment of CEO Bill Anderson -- a former Roche executive -- in 2023, the company has been focused on restructuring and streamlining its business. The pharmaceutical division has been under pressure from looming patent expirations and generic competition for several blockbuster drugs. Bayer's M&A engine had been dormant for nearly five years in pharma: its last drug company purchase was Vividion Therapeutics for $1.5 billion in August 2021, and before that, AskBio for up to $4 billion in October 2020 and KaNDy Therapeutics for $875 million in August 2020.

Stefan Oelrich, Bayer's head of pharmaceuticals, had indicated in recent interviews that the company was actively negotiating multiple deals. The Perfuse transaction validates that claim and signals a broader strategic re-engagement with external innovation.

Bayer's ophthalmology portfolio positioning is notable. The company does not develop or manufacture medical devices itself, but its marketing rights to Eylea products give it deep commercial infrastructure and physician relationships in the retina and ophthalmology space globally (outside the US). In 2025, Bayer reported $3.3 to $3.6 billion in Eylea revenue, a 5.9% year-on-year decline attributable to growing biosimilar competition as key patents expired. Eylea's formulation patents begin expiring on June 14, 2027, with Eylea HD patents expiring between 2027 and 2032. As Juergen Eckhardt, EVP and head of business development & licensing at Bayer Pharmaceuticals, noted: "We are always looking for opportunistic assets and companies that can help us complement our current portfolio. Here, we will leverage our Eylea expertise and team." PER-001 fits squarely within this therapeutic focus area and provides a potential successor growth driver as Eylea faces patent headwinds.

Perfuse Therapeutics: A Venture-Backed Ophthalmology Innovator

Perfuse Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, with R&D facilities in Durham, North Carolina. The company was founded to pursue transformational therapies for ischemia-induced ocular diseases -- conditions driven by inadequate blood flow to retinal tissues.

The company's founder and CEO is Sevgi Gurkan, MD, a physician-scientist who assembled a team with deep expertise in ocular drug discovery, drug delivery and formulation, and clinical development. Perfuse has been backed by a syndicate of leading venture capital firms with ophthalmology market expertise, including Catalio Capital Management, which had supported the company from its seed round through Phase 2 readouts in both glaucoma and diabetic retinopathy.

Perfuse's entire value proposition rests on a single asset -- PER-001 -- and its proprietary sustained-release drug delivery platform. The company has operated with the kind of focused, single-asset intensity that is characteristic of the most successful venture-backed biotechs: identify a validated biological pathway, develop a first-in-class molecule targeting that pathway, engineer a delivery system optimized for the target tissue, and advance rapidly through clinical development with lean, focused trials.

PER-001: The Science and Clinical Program

Mechanism of Action: Endothelin Receptor Antagonism

PER-001 is a novel small molecule endothelin receptor antagonist (ERA) -- the first of its class developed specifically for ophthalmic indications. To understand why this mechanism matters, it is necessary to understand the role of endothelin in ocular disease.

Endothelin-1 (ET-1) is the most potent vasoconstrictor in the human body. It is upregulated in multiple ocular diseases, including glaucoma, diabetic retinopathy, age-related macular degeneration (AMD), and retinal vein occlusion (RVO). Through its receptors -- particularly the endothelin receptor A (ETaR), which PER-001 selectively targets -- endothelin drives a cascade of pathological processes in retinal tissue:

• Vasoconstriction: ET-1 constricts retinal blood vessels, reducing blood flow to the optic nerve head and retinal tissues. This chronic hypoperfusion leads to ischemia -- oxygen and nutrient deprivation.
• Inflammation: Endothelin signaling activates inflammatory pathways in retinal vascular and neuroretinal cells, contributing to tissue damage.
• Cell death (apoptosis): Sustained endothelin signaling promotes retinal ganglion cell (RGC) death in glaucoma and vascular endothelial cell damage in diabetic retinopathy.
• Neovascularization and fibrosis: In diabetic retinopathy, endothelin contributes to pathological new blood vessel formation and vascular leak.

The endothelin pathway is clinically validated beyond ophthalmology. Multiple ERA drugs have been approved for systemic indications, including pulmonary arterial hypertension (ambrisentan, bosentan, macitentan) and resistant systemic hypertension. Perfuse's insight was to apply this validated mechanism locally -- delivering an ERA directly to the eye via an intravitreal implant -- to address the underlying vascular pathology in blinding eye diseases.

The Drug-Device Combination: Intravitreal Implant Design

PER-001 is not administered as a simple eye drop or intravitreal injection. It is formulated as a bio-erodible intravitreal implant -- a small, rod-shaped polymeric device that is injected into the vitreous cavity of the eye using a single-use, 25-gauge applicator. Once implanted, the device gradually erodes, releasing PER-001 in a sustained fashion over approximately six months.

The implant utilizes PLGA (poly(lactic-co-glycolic acid)) polymer technology -- the same validated and safe biodegradable polymer found in other sustained-release intravitreal products, including Ozurdex (dexamethasone intravitreal implant, marketed by AbbVie). The preloaded applicator contains a 4 mm implant with a volume of 0.36 microliters, equipped with a retention wire for precise placement.

This design offers several critical advantages:

• Sustained local delivery: The implant maintains therapeutic drug levels in the vitreous and retina for up to six months from a single administration, avoiding the peaks and troughs associated with repeated injections.
• Convenient dosing interval: A six-month dosing frequency dramatically reduces treatment burden compared to monthly or bimonthly anti-VEGF injections that dominate current ophthalmic practice.
• Minimal invasiveness: The 25-gauge applicator is standard for intravitreal procedures and can be administered in an office setting by a trained ophthalmologist.
• Bio-erodible: The implant dissolves completely, eliminating the need for surgical removal (unlike some non-biodegradable implants such as Retisert).

This drug-device combination places PER-001 squarely within the regulatory framework for combination products -- products composed of two or more regulated components (drug and device) that are physically or chemically combined.

Clinical Development and Trial Results

PER-001 has progressed through a disciplined clinical development program with encouraging results across multiple ocular indications.

Phase 1/2a Trial in Glaucoma

The first-in-human study evaluated PER-001 in patients with glaucoma. The Phase 1 component was an open-label study testing two dose levels in patients with advanced glaucoma. The Phase 2a component was a randomized, masked study comparing low and high doses of PER-001 against a sham control in patients with mild-to-moderate glaucoma. All patients continued their existing intraocular pressure (IOP)-reducing therapies.

Key 24-week results, presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting by Steven Mansberger, MD, MPH, Chief of Ophthalmology and Director of Glaucoma Services at Legacy Devers Eye Institute:

• PER-001 was safe and well tolerated. The only drug-related adverse event was a single case of vitreous floater (mild and transient). There were no drug-related serious adverse events and no reports of intraocular inflammation.
• Patients treated with PER-001 showed a mean increase in optic nerve head blood flow of at least 10% from baseline starting at Week 1, sustained through Week 24.
• The increase in blood flow was associated with a mean improvement in visual field mean deviation of approximately 1 dB per year and a mean increase in retinal nerve fiber layer (RNFL) thickness of up to +7.7 microns per year (low dose) on OCT imaging, compared to a decrease of -6.8 microns per year in the sham control group.

Phase 2a Trials in Glaucoma and Diabetic Retinopathy

In June 2025, Perfuse announced positive results from two Phase 2 clinical trials, each six months in duration and randomized sham-controlled. A total of 60 patients participated: 33 with glaucoma and 27 with diabetic retinopathy.

Glaucoma Phase 2a (NCT05822245) -- 36 patients:

• 37.5% of high-dose patients experienced a clinically meaningful improvement of 7 dB or more in visual field sensitivity in predefined retinal regions, compared to 0% in the control group.
• 22.2% of low-dose patients achieved the same threshold.
• This improvement was 8 to 14 times better than the natural history of disease (2.7%) with currently available treatments.
• No PER-001-treated patient experienced a loss of 7 dB or more in visual field, compared to 12.5% in the control group -- a rate consistent with known disease progression.
• Improvements in ocular blood flow and optic nerve structure (OCT RNFL thickness) were also observed.
• A strong, linear relationship between functional (visual field) and structural (RNFL) improvements was demonstrated (Pearson Correlation Coefficient = 0.721; p = 0.0003; R-squared = 0.52).

Joel Schuman, MD, professor at Wills Eye Hospital and president of the Collaborative Community on Ophthalmic Innovation, characterized these results as demonstrating "neuroenhancement -- improvement in the function of existing optic nerve tissue -- in humans with glaucoma" for the first time.

Diabetic Retinopathy Phase 2a (NCT06003751) -- 27 patients:

• The high-dose group showed a mean improvement of +0.9 dB in low luminance contrast sensitivity; the low-dose group improved by +0.65 dB across multiple frequencies at Week 20.
• The control group worsened by a mean of -2.1 dB over the same period.
• Low luminance, low contrast visual acuity was better by a mean difference of 5.5 letters (low dose) and 5.1 letters (high dose) from baseline compared to control at Week 20.
• Structural improvements were observed in macular ischemia, vascular leakage, and microaneurysm count as measured by ultra-widefield fluorescein angiography (UWFA).

Arshad Khanani, MD, Clinical Professor of Ophthalmology at the University of Nevada and Director of Clinical Research at Sierra Eye Associates, stated: "For the first time, we're seeing a therapy for diabetic retinopathy that shows improvement in visual function... By targeting the endothelin pathway, PER-001 introduces a novel, every 6 months therapy that can address the underlying neurovascular disease."

Future Indications

Beyond glaucoma and diabetic retinopathy, Perfuse has also positioned PER-001 as a potential therapy for dry age-related macular degeneration (AMD) and retinal vein occlusion (RVO). These programs are in preclinical or early-stage development, but they represent significant market expansion opportunities given the epidemiology of these conditions.

Why This Deal Matters for MedTech

Bayer's Strategic Calculus

The Perfuse acquisition is significant for several reasons that extend beyond Bayer's specific portfolio:

End of a five-year M&A drought. Bayer's last drug company acquisition was Vividion Therapeutics in August 2021. For nearly five years, the German pharma giant abstained from pharmaceutical M&A while it navigated internal restructuring, litigation over glyphosate (Roundup), and the strategic re-evaluation initiated by CEO Bill Anderson. The Perfuse deal signals that Bayer is ready to deploy capital on external innovation again -- and that ophthalmology is a priority therapeutic area.

Validation of the drug-device combination model. By paying up to $2.45 billion for a Phase II asset delivered via an intravitreal implant, Bayer is placing a substantial bet that drug-device combination products will define the next generation of ophthalmic therapeutics. This is not a bet on a small-molecule pill or a biologic injection; it is a bet on sustained-release implant technology that integrates drug formulation, polymer science, and delivery device engineering.

Disease-modifying potential. Perhaps most importantly, PER-001 has demonstrated something rarely seen in ophthalmic drug development: the potential to not merely slow disease progression but to actually improve visual function. In glaucoma, where no approved treatment prevents disease progression independently of IOP reduction, and in diabetic retinopathy, where current therapies manage complications rather than reverse damage, the prospect of a disease-modifying therapy is transformational.

Deal Structure and Risk Allocation

The deal's financial structure is notable and reflects the risk profile of acquiring a Phase II asset:

This structure is characteristic of biopharma acquisitions of clinical-stage assets and differs from the typical medical device M&A profile, where acquisitions are more often structured with higher upfront components relative to milestones. The heavy milestone weighting reflects the inherent clinical and regulatory risk of a Phase II drug candidate.

The Ophthalmology Drug-Device Market

Market Size and Growth Trajectory

The ophthalmic drug and device market represents one of the most attractive growth segments in healthcare, driven by aging populations, rising diabetes prevalence, and unmet medical need.

The intravitreal drug delivery segment is the fastest-growing sub-segment within ophthalmic drug delivery, projected to grow at a CAGR of 8.37% from 2025 to 2030. Anti-VEGF injections remain the dominant modality, accounting for approximately 67% of the retinal biologics market in 2024, but treatment fatigue among patients receiving monthly or bimonthly injections is a recognized and growing limitation.

The Patient Burden

The epidemiological case for ophthalmic innovation is overwhelming:

Diabetic Retinopathy:

• Approximately 103 million adults worldwide have diabetic retinopathy.
• The number is projected to reach 160.5 million by 2045.
• Vision-threatening diabetic retinopathy (VTDR) affects approximately 28.5 million people globally, projected to rise to 44.8 million by 2045.
• In the United States alone, an estimated 9.6 million people (26.4% of those with diabetes) had diabetic retinopathy in 2021, with 1.84 million experiencing vision-threatening DR.
• DR is the leading cause of blindness among working-age adults worldwide.

Glaucoma:

• Glaucoma affects approximately 76-80 million people worldwide (2020 data) and is projected to affect approximately 112 million people by 2040 due to population aging.
• It is the leading cause of irreversible blindness globally.
• Despite current standard of care (IOP-lowering therapies, both pharmacological and surgical), many patients continue to lose vision even with normal pressure levels.
• No approved treatment prevents disease progression independently of IOP reduction -- a massive unmet medical need.

Age-Related Macular Degeneration:

• AMD affects approximately 2.1 million Americans, with the number projected to reach 3.6 million by 2030.
• Dry AMD/geographic atrophy represents a particularly underserved population with few approved treatment options.

Regulatory Pathway for Intravitreal Implants

FDA Combination Product Framework

PER-001 is a drug-device combination product, and its regulatory pathway through the FDA reflects this classification. Understanding this pathway is essential for medtech professionals because the intersection of drug and device regulation is becoming increasingly important in ophthalmology.

What Constitutes a Combination Product?

Under 21 CFR 3.2(e), a combination product is defined as a product comprising two or more regulated components (drug and device, biologic and device, or drug and biologic) that are physically, chemically, or otherwise combined or mixed as a single entity. For PER-001, the drug constituent part is the endothelin receptor antagonist small molecule, and the device constituent part is the bio-erodible PLGA intravitreal implant and its 25-gauge single-use applicator.

Primary Mode of Action (PMOA) Determination

The FDA's Office of Combination Products (OCP) determines which FDA center will have primary jurisdiction based on the product's Primary Mode of Action (PMOA) -- defined as "the single mode of action of a combination product that provides the most important therapeutic action."

For PER-001, the PMOA is pharmacological: the endothelin receptor antagonist provides the primary therapeutic benefit by blocking endothelin signaling, reducing vasoconstriction, and improving retinal blood flow. The implant serves as a delivery vehicle. Accordingly, the Center for Drug Evaluation and Research (CDER) would be expected to serve as the lead review center, with the Center for Devices and Radiological Health (CDRH) consulting on the device constituent part.

Regulatory Submission Pathway

For drug-led combination products with a CDER lead, the typical submission pathway is a New Drug Application (NDA) under Section 505(b)(1) or 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. The NDA must include:

• Complete drug substance and drug product information (Chemistry, Manufacturing, and Controls)
• Device constituent part information, including design elements, performance characteristics, biocompatibility data, and accelerated aging data
• Clinical data demonstrating safety and efficacy of the combination product as a whole
• Manufacturing compliance with both drug current Good Manufacturing Practices (cGMP) under 21 CFR Parts 210/211 and device Quality System Regulation requirements under 21 CFR Part 820, as governed by 21 CFR Part 4 for combination products

The sponsor may submit a single application covering both the drug and device components, as encouraged by Section 503(g)(1)(B) of the FD&C Act, or may submit separate applications (e.g., an NDA for the drug and a separate device application).

Precedent Products

Several intravitreal implant drug-device combination products have been approved by the FDA, establishing regulatory precedent for PER-001:

Ozurdex is particularly relevant as a comparator because it also uses PLGA biodegradable polymer technology and is administered via a similar applicator system. The established safety and regulatory precedent for PLGA-based intravitreal implants should support a clearer pathway for PER-001.

EU Regulatory Considerations

In the European Union, combination products are regulated under the Medical Device Regulation (MDR 2017/745) and the medicinal product directives, depending on the nature and primary mode of action of the product. If the product's action is primarily achieved by the medicinal product (drug), it is regulated as a medicinal product under the EMA framework, with the device component assessed as part of the quality and safety data. Given Bayer's strong ex-US commercial presence and Eylea marketing rights, PER-001 will likely pursue parallel regulatory pathways in the US and EU.

Competitive Landscape in Ophthalmology

Anti-VEGF Dominance and Its Limitations

The ophthalmology drug market is dominated by anti-VEGF (vascular endothelial growth factor) therapies, which are the standard of care for wet AMD, diabetic macular edema, and proliferative diabetic retinopathy. The major anti-VEGF products include:

• Eylea/Eylea HD (Regeneron/Bayer): Aflibercept 2 mg and 8 mg. Bayer holds ex-US rights. Combined global sales exceeded $11 billion at peak.
• Vabysmo (Roche/Genentech): Faricimab, a bispecific antibody targeting both VEGF-A and Ang-2. US sales surpassed combined Eylea sales in Q2 2025, indicating strong market adoption.
• Lucentis (Roche/Novartis): Ranibizumab, now facing biosimilar competition from Byooviz and others.
• Beovu (Novartis): Brolucizumab, approved but with safety concerns that have limited adoption.

Anti-VEGF therapy has transformed ophthalmic care, but it has inherent limitations that create opportunities for alternatives like PER-001:

1. Treatment burden: Most anti-VEGF agents require intravitreal injections every 4-8 weeks, at least initially. Patient non-compliance and missed appointments lead to suboptimal outcomes.
2. Limited mechanism: Anti-VEGF addresses neovascularization and vascular leak but does not target the underlying ischemia and neurodegeneration that drive disease progression.
3. Non-response: A significant minority of patients show incomplete or no response to anti-VEGF therapy.
4. Glaucoma gap: Anti-VEGF agents are not indicated for glaucoma, which is driven by a fundamentally different pathology (optic neuropathy and retinal ganglion cell death) than the vascular leakage targeted by anti-VEGF.

The Emerging Competitive Set for PER-001

PER-001's competitive position is unique because it targets indications and mechanisms that are distinct from anti-VEGF:

In glaucoma, the current treatment paradigm is almost entirely focused on IOP reduction -- through topical eye drops (prostaglandin analogs, beta-blockers, alpha-agonists, carbonic anhydrase inhibitors), laser trabeculoplasty, or surgical interventions (MIGS devices, trabeculectomy). PER-001 would be the first therapy to address the neurodegenerative and vascular components of glaucoma independently of IOP. There are no directly competing products in late-stage clinical development with this mechanism.

In diabetic retinopathy, PER-001 would compete with anti-VEGF agents for the NPDR (non-proliferative DR) population but would differentiate through its novel mechanism (endothelin antagonism vs. VEGF inhibition), its six-month dosing interval, and its potential to actually improve visual function rather than merely prevent worsening.

Sustained-release delivery competitors include Genentech's Susvimo port delivery system (for ranibizumab in AMD and DME), which offers continuous drug delivery via a surgically implanted refillable port, and various PLGA-based implants in development. EyePoint Pharmaceuticals' DEXYCU (dexamethasone intraocular suspension) and YUTIQ (fluocinolone acetonide intravitreal implant) compete in the sustained-release ophthalmic space, though for different indications (post-surgical inflammation and uveitis, respectively).

What This Means for Device Manufacturers and Investors

Implications for Drug-Device Combination Product Developers

The Bayer-Perfuse deal validates several trends that should inform strategic planning for ophthalmic medtech companies:

1. Sustained-release implant technology is a validated commercial platform. The fact that Bayer is willing to pay up to $2.45 billion for a Phase II asset delivered via a PLGA bio-erodible implant confirms that large pharma companies see sustained-release intravitreal delivery as a critical component of next-generation ophthalmic therapy. Device manufacturers with expertise in biodegradable polymers, implant formulation, and precision applicator design are well-positioned to partner with or be acquired by pharma companies seeking to develop combination products.

2. The six-month dosing interval is becoming a competitive standard. The current standard of monthly or bimonthly anti-VEGF injections is unsustainable from both a patient burden and healthcare cost perspective. PER-001's six-month dosing aligns with the broader industry trend toward extended-duration therapies. Eylea HD (8 mg) extended the dosing interval to 12-16 weeks; Susvimo offers continuous delivery; and several gene therapy approaches aim for one-time treatment. Companies developing delivery technologies that extend dosing intervals will find strong demand from pharma partners.

3. Neuroprotection and vascular mechanisms are the next frontier. The anti-VEGF market is mature and increasingly competitive, with biosimilar entry expected to erode pricing. The next wave of innovation in ophthalmology will target different pathways -- endothelin, complement, neurotrophic factors -- that address the underlying disease processes rather than downstream effects. Device companies that can deliver these novel agents to the retina in sustained fashion will be essential partners.

4. Combination product regulatory expertise is a differentiator. Navigating the intersection of drug and device regulation (21 CFR Part 4, PMOA determination, dual-center FDA review) requires specialized expertise that most pure-play device or drug companies lack. Companies and consultants with demonstrated combination product regulatory experience will command premium value as more drug-device convergence deals are struck.

Investment and Deal Activity Outlook

The Bayer-Perfuse transaction is likely to catalyze further deal activity in ophthalmic drug-device convergence:

• Platform companies with sustained-release delivery technology -- particularly those using PLGA, injectable hydrogels, or novel biodegradable polymers -- will attract acquirer interest.
• Clinical-stage ophthalmic biotechs with novel mechanisms (endothelin antagonists, complement inhibitors, gene therapies) will see increased valuation as the Bayer deal provides a new comparable transaction.
• Large medtech companies with ophthalmology portfolios (Alcon, Bausch & Lomb, Carl Zeiss Meditec, Johnson & Johnson Vision) may accelerate their own combination product strategies to compete with pharma entrants like Bayer.
• The ophthalmology devices market, valued at approximately $71 billion in 2024 and projected to reach $93 billion by 2030, will see increasing convergence between pharmaceutical and device development as drug-device combinations become a larger share of the total market.

Key Risk Factors

Investors and industry participants should consider several risk factors:

• Clinical risk: PER-001 is a Phase II asset. While Phase 2a results are encouraging, pivotal trials (Phase 2b/3) have not yet been initiated. Many promising ophthalmic therapies have failed in late-stage development.
• Regulatory risk: As a first-in-class drug-device combination with a novel mechanism, PER-001 will face rigorous regulatory scrutiny. The FDA may require additional device testing, long-term safety data, or larger pivotal trials.
• Commercial risk: Even if approved, PER-001 will need to compete against entrenched anti-VEGF therapies with decades of safety data and physician familiarity. Payer reimbursement for a novel mechanism at a premium price is not guaranteed.
• Integration risk: Bayer has limited recent experience integrating pharma acquisitions. The company's "arm's length" model for acquired companies (used with AskBio, Vividion, BlueRock) may or may not be optimal for Perfuse's stage of development.

Key Takeaways

1. Bayer's $2.45 billion acquisition of Perfuse Therapeutics (announced May 6, 2026) marks the end of a nearly five-year pharma M&A drought for the German healthcare giant and signals renewed strategic commitment to ophthalmology.

2. PER-001 is a first-in-class endothelin receptor antagonist delivered via a bio-erodible PLGA intravitreal implant using a 25-gauge applicator, designed for six-month dosing. It is the most advanced ERA in ophthalmic development.

3. Phase 2a results demonstrated something unprecedented: actual improvement in visual function in both glaucoma (37.5% of high-dose patients achieving clinically meaningful visual field gains) and diabetic retinopathy (contrast sensitivity improvements with structural benefits), not merely slowing of progression.

4. The deal is a drug-device combination product transaction, placing it at the intersection of pharmaceutical and medical device regulatory pathways. FDA review will involve CDER as lead center with CDRH consultation on the implant and applicator device components.

5. The ophthalmology market is large and growing, with global ophthalmology drugs projected to reach $26.3 billion by 2030 and ophthalmic drug delivery systems projected to reach $23.4 billion. The intravitreal delivery sub-segment is growing at 8.37% CAGR.

6. Diabetic retinopathy affects approximately 103 million people globally, projected to reach 160.5 million by 2045. Glaucoma affects 76-80 million people worldwide and is the leading cause of irreversible blindness. The unmet need for disease-modifying therapies in both conditions is enormous.

7. Bayer's existing ophthalmology commercial infrastructure -- built through its ex-US Eylea marketing rights -- provides a ready-made global commercial platform for PER-001 if approved.

8. The deal structure ($300M upfront + $2.15B milestones) reflects the clinical-stage risk profile, with 88% of total deal value contingent on development, regulatory, and commercial success. This is characteristic of pharma-biotech acquisitions and differs from typical medical device M&A structures.

9. The transaction is subject to antitrust clearance and Perfuse stockholder approval and is being advised by BofA Securities and Baker McKenzie (Bayer) and Centerview Partners and Goodwin Procter (Perfuse).

10. For medtech manufacturers and investors, the deal confirms that drug-device combination products -- particularly sustained-release intravitreal implants -- represent one of the highest-value opportunities in ophthalmic innovation. Companies with expertise in biodegradable polymer technology, implant formulation, and combination product regulatory navigation are strategically well-positioned.

Sources: Bayer AG press release (May 6, 2026); Perfuse Therapeutics press releases (May 2025, June 2025); BioSpace; Fierce Biotech; GEN News; Reuters; Yahoo Finance/BioPharma Dive; Ophthalmology Management; Eyewire+; Citybiz; Baker McKenzie newsroom; Goodwin Procter newsroom; Conexiant; Teo et al., Ophthalmology (2021) -- Global Prevalence of Diabetic Retinopathy; Prevent Blindness / JAMA Ophthalmology (2021 US prevalence data); Grand View Research; MarketsandMarkets; Research and Markets.